Rolf van Heeswijk
Overview
Explore the profile of Rolf van Heeswijk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
764
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Heeswijk R, Verboven P, Vandevoorde A, Vinck P, Snoeys J, Boogaerts G, et al.
Antimicrob Agents Chemother
. 2013 Mar;
57(5):2304-9.
PMID: 23478952
Hepatitis C virus (HCV) antibody is present in most patients enrolled in methadone maintenance programs. Therefore, interactions between the HCV protease inhibitor telaprevir and methadone were investigated. The pharmacokinetics of...
2.
Dooley K, Park J, Swindells S, Allen R, Haas D, Cramer Y, et al.
J Acquir Immune Defic Syndr
. 2011 Dec;
59(5):455-62.
PMID: 22126739
Background: Drug-drug interactions complicate management of coinfection with HIV-1 and Mycobacterium tuberculosis. Bedaquiline (formerly TMC207), an investigational agent for the treatment of tuberculosis, is metabolized by cytochrome P450 (CYP) 3A...
3.
Garg V, van Heeswijk R, Yang Y, Kauffman R, Smith F, Adda N
J Clin Pharmacol
. 2011 Nov;
52(10):1574-83.
PMID: 22039291
Background: Telaprevir is a hepatitis C virus protease inhibitor that is both a substrate and an inhibitor of CYP3A. Study Design: The effect of steady-state telaprevir (administered 750 mg every...
4.
Lee J, van Heeswijk R, Alves K, Smith F, Garg V
Antimicrob Agents Chemother
. 2011 Aug;
55(10):4569-74.
PMID: 21825288
Telaprevir is a hepatitis C virus protease inhibitor that is both a substrate and an inhibitor of CYP3A. Amlodipine and atorvastatin are both substrates of CYP3A and are among the...
5.
Foster G, Hezode C, Bronowicki J, Carosi G, Weiland O, Verlinden L, et al.
Gastroenterology
. 2011 Jun;
141(3):881-889.e1.
PMID: 21699786
Background & Aims: We evaluated antiviral activity of 2 weeks therapy with telaprevir alone, peginterferon alfa-2a and ribavirin (PR), or all 3 drugs (TPR) in treatment-naïve patients with chronic hepatitis...
6.
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al.
N Engl J Med
. 2011 Jun;
364(25):2417-28.
PMID: 21696308
Background: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virologic response to therapy with peginterferon alfa plus ribavirin. Methods: In...
7.
Garg V, van Heeswijk R, Lee J, Alves K, Nadkarni P, Luo X
Hepatology
. 2011 May;
54(1):20-7.
PMID: 21618566
Unlabelled: The hepatitis C virus protease inhibitor telaprevir is an inhibitor of the enzyme cytochrome P450 3A, responsible for the metabolism of both cyclosporine and tacrolimus. This Phase I, open-label,...
8.
Marcellin P, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, et al.
Gastroenterology
. 2010 Nov;
140(2):459-468.e1.
PMID: 21034744
Background & Aims: Recent studies have shown that 12 weeks of treatment with telaprevir, administered every 8 hours (q8h), combined with pegylated interferon (peginterferon) alfa-2a plus ribavirin significantly increased the...
9.
Arasteh K, Rieger A, Yeni P, Pozniak A, Boogaerts G, van Heeswijk R, et al.
Antivir Ther
. 2009 Aug;
14(5):713-22.
PMID: 19704175
Background: In vitro, TMC278, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), has shown activity against wild-type and NNRTI-resistant HIV type-1 (HIV-1) and a higher genetic barrier to the development...
10.
Porte C, van Heeswijk R, Mitchell C, Zhang G, Parker J, Rongkavilit C
Antivir Ther
. 2009 Jul;
14(4):603-6.
PMID: 19578247
Background: Once-daily lopinavir/ritonavir (LPV/r) is not approved for treatment of HIV paediatric patients. Once daily treatment in children might serve the same goals of patient comfort and adherence as in...